American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • 2017
  • »
  • July

Sun Pharmaceuticals moves ahead with psoriasis-treating drug

American Pharmacy News Reports | Jul 28, 2017
Sun Pharmaceutical’s BLA filing for the drug comes after two Phase III trials.

Sun Pharmaceutical Industries Ltd.'s Biologics License Application for tildrakizumab has been accepted by the U.S. Food and Drug Administration. Read More »

Xynomic Pharma teams with UCSF for PAX Study

American Pharmacy News Reports | Jul 28, 2017
The study will use data from Xynomic Pharma’s Phase 1b study, which was sponsored by the National Cancer Institute.

Xynomic Pharma's has initiated a strategic partnership with the University of California San Francisco for a PAX Study – a multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat, as opposed to Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma. Read More »

AstraZeneca taps Biologics to distribute carcinoma drug

American Pharmacy News Reports | Jul 28, 2017
Patients diagnosed with advance bladder cancer often start receiving platinum-containing chemotherapy.

Biologics Inc., a McKesson Specialty Health oncology pharmacy services company, has been chosen by AstraZeneca to distribute Imfinzi. Read More »

Amgen and UCB release positive results for Evenity study

American Pharmacy News Reports | Jul 28, 2017
Patients given Evenity for 12 months followed by alendronate saw reductions in vertebral fracture incidents.

Amgen and UCB recently announced that their Evenity study, which analyzed the drug as a treatment for postmenopausal women with osteoporosis, met both primary endpoints and the secondary endpoint. Read More »

Therigy partners with EPI-W to expand research on specialty pharmacy outcomes

American Pharmacy News Reports | Jul 28, 2017
Therigy noted that EPI-Q brings more than 20 years of experience to the research table.

Therigy, a company that pioneered patient-focused specialty therapy management, recently announced a strategic partnership with EPI-Q Inc. to expand research on specialty pharmacy outcomes. Read More »

FDA approves Sanofi's Kevzara for rheumatoid arthritis treatment

American Pharmacy News Reports | Jul 30, 2017
Sanofi's CEO said rheumatoid arthritis patients continue to need new treatment options.

Sanofi and Regeneron Pharmaceuticals Inc. recently announced that Kevzara (sarilumab), a treatment for adult patients with moderately to severely active rheumatoid arthritis who have not responded well to one or more disease modifying antirheumatic drugs, has been approved by the U.S. Food and Drug Administration. Read More »

Good Neighbor Pharmacy network adds fee estimator tool

American Pharmacy News Reports | Jul 30, 2017
AmerisourceBergen strives to simplify industry challenges for independent pharmacists via its Good Neighbor Pharmacy initiative.

Pharmaceutical provider AmerisourceBergen recently unveiled the DIR Fee Estimator, its newest tool in conjunction with its nationwide Good Neighbor Pharmacy network, to streamline transactions between provider networks and pharmacy benefit managers by providing cost estimate ranges. Read More »

FDA clears first neonatal MRI device

American Pharmacy News Reports | Jul 31, 2017
The Embrace Neonatal MRI System is designed specifically for imaging of the neonatal head.

To better tend babies in the nation’s neonatal intensive care units, the first magnetic resonance imaging (MRI) device designed for newborns recently garnered U.S. Food and Drug Administration approval following thorough safety confirmation. Read More »

FDA accepts Amgen’s BLA for Aimovig (erenumab)

American Pharmacy News Reports | Jul 31, 2017
kind, according to the company: a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor.  Data was gleaned from studies involving over 2,600 patients.

California-based Amgen recently obtained U.S. Food and Drug Administration (FDA) acceptance of its Biologics License Application (BLA) for Aimovig (erenumab), a product developed specifically to help victims of frequent migraine headaches. Read More »

Chinese officials accept study application for GBM treatment

American Pharmacy News Reports | Jul 31, 2017
The company will begin enrollment for the trial in the next few weeks at Sun Yat-sen University Cancer Center.

DelMar Pharmaceuticals' application for a Phase II study evaluating a treatment for newly diagnosed MGMT-unmethylated glioblastoma multiforme has been accepted by the Human Genetic Resources Administration of China. Read More »

Luminex Corp.'s c. difficile assay attains FDA clearance

American Pharmacy News Reports | Jul 31, 2017
C. difficile is an urgent threat as it is now the most common microbial cause of health care-associated infections in U.S. hospitals.

Luminex Corporation recently announced that its ARIES clostridium difficile (c. difficile) assay has been given U.S. Food and Drug Administration (FDA) clearance. Read More »

Health Canada to review Sunovion's schizophrenia treatment

American Pharmacy News Reports | Jul 31, 2017
Schizophrenia is a critical, often disabling brain disorder.

Sunovion Pharmaceuticals Inc. of Marlborough, Massachusetts recently gained approval for its supplemental new drug submission regarding Latuda (lurasidone HCI) — aimed at relieving adolescent schizophrenia — from Health Canada, potentially extending the treatment’s age range. Read More »

  • «
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • »
Trending

Dr. Allison Hill DC State Board of Pharmacy Chairperson

Modified services and closures announced for DC Emancipation Day observance

 Jeff Harrell Board President

Arkansas law bans PBMs from pharmacy ownership to curb anti-competitive practices

Shaun Noorian, Founder, CEO & Chairman, Empower Pharmacy

Empower Pharmacy ranks among fastest-growing private firms in Southwest

 Jeff Harrell Board President

NCPA reacts to Trump's drug pricing executive order targeting pharmacy benefit managers

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up